CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Canadian SCAD Cohort Study: Shedding Light on SCAD From a United Front Prognostic Value of Fractional Flow Reserve Measured Immediately After Drug-Eluting Stent Implantation Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation Association Between Diastolic Dysfunction and Health Status Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents

Editorial2017 Oct 1;2(10):1061-1062.

JOURNAL:JAMA Cardiol. Article Link

What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis?

Ruel M, Verma S, Bhatt DL. Keywords: PCI; CABG; repeat revascularization

ABSTRACT

Over the last months, 2 major trials and several meta-analyses have been published on the treatment of stable, unprotected left main coronary artery stenosis. Currently, North American and European guidelines for the treatment of left main stenosis indicate a class I recommendation for the performance of coronary artery bypass grafting (CABG). They also indicate a class IIa to III (North American) or a class I to III (European) recommendation for percutaneous coronary intervention (PCI), depending on the complexity of the coronary anatomy as determined by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score.